Staff turnover in FDA's Office of the Chief Counsel is a positive, says the agency's top lawyer Elizabeth Dickinson. The chief counsel also discussed recent device bans, off-label communication policy efforts and the agency’s ongoing transparency initiative at the annual Food & Drug Law Institute conference.
Turnover among FDA’s lawyers is not uncommon, admits Elizabeth Dickinson, the agency's chief counsel, but she argues that the churn benefits both the agency and its stakeholders.
“Although we are always sad to lose [Office of the Chief Counsel] colleagues, the flow of talent among OCC, our...